BioCentury
ARTICLE | Politics, Policy & Law

Dynamic pricing for value

September 25, 2006 7:00 AM UTC

GlaxoSmithKline plc has unveiled a new approach to discussing reimbursement with European payers that involves a tacit agreement that initial prices can be amended both upwards or downwards based on additional post-launch data. GSK hopes the result will be a focus on value rather than price, and drive the company toward developing truly novel medicines.

The deals reflect the mounting pressure on drug companies to provide evidence of value as well as proof of efficacy(see BioCentury, Sept. 4). ...